ArticlePerioperative medicine (London, England)2025
The impact of sugammadex versus neostigmine reversal on return to intended oncological therapy-related outcomes after breast cancer surgery: a retrospective cohort study.
Article in Perioperative medicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEarly return to intended oncological therapy (RIOT) after cancer resection is a determinant for long-term oncological outcomes. Sugammadex is increasingly used to reverse the muscle relaxant effect of rocuronium during general anesthesia. It has been shown to improve early postoperative outcomes, but its impact on RIOT is unknown. This study tested the hypothesis that the administration of sugammadex during mastectomy for nonmetastatic breast cancer resection would be associated with better RIOT-related outcomes compared with neostigmine.
methodsWomen ≥ 18 years who required mastectomy for nonmetastatic breast cancer resection from 2015 to 2022 were included in the retrospective study. They were grouped according to the administration of sugammadex or neostigmine. The study outcomes included time to RIOT, the incidence of RIOT at 90 and 180 days, length of hospital stay, and rate of 30-day hospital readmission. A multivariate analysis was conducted to test the association between sugammadex use and RIOT-related outcomes.
resultsOf 888 patients who met the study criteria, 319 received neostigmine and 569 received sugammadex. Sugammadex patients achieved RIOT at 90 days in 81.9% of the cases, whereas 70.8% of neostigmine patients were able to achieve RIOT (P < 0.001). Similar results were found for RIOT at 180 days (85.8% vs. 76.8%, respectively; P < 0.001). Sugammadex patients achieved RIOT faster than neostigmine patients (37 days, 95% CI: 35-41 days; P < 0.001). However, the multivariate analysis for RIOT initiation and time to RIOT did not show statistically significant differences.
conclusionThe administration of sugammadex, compared with neostigmine, is not associated with significant improvements in RIOT-related variables after breast cancer surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.